SAM
AKRO

Smartleaf Asset Management’s Akero Therapeutics AKRO Stock Holding History

Smartleaf Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-675
Closed -$32.1K – 3492
2025
Q3 		$32.1K Buy
675
+442
+190% +$21.4K ﹤0.01% 1602
2025
Q2 		$13.1K Sell
233
-352
-60% -$16K ﹤0.01% 1725
2025
Q1 		$25K Buy
585
+187
+47% +$7.93K ﹤0.01% 1491
2024
Q4 		$11.1K Buy
398
+223
+127% +$6.75K ﹤0.01% 1947
2024
Q3 		$4.94K Buy
175
+3
+2% +$78 ﹤0.01% 2124
2024
Q2 		$4.02K Buy
172
+102
+146% +$2.18K ﹤0.01% 1903
2024
Q1 		$1.71K Buy
+70
New +$1.68K ﹤0.01% 1502

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Smartleaf Asset Management's AKRO Position: Q4 2025 in Review

Smartleaf Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 675 shares — an estimated $32.1K sold.

Smartleaf Asset Management first reported a position in AKRO in Q1 2024 and held it in 7 quarters. The position peaked at $32.1K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Smartleaf Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 675 Akero Therapeutics shares in Q4 2025, an estimated $32.1K.
  • Smartleaf Asset Management first reported a position in Akero Therapeutics in Q1 2024 and held it in 7 quarters.
  • Smartleaf Asset Management's Akero Therapeutics position peaked at $32.1K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Smartleaf Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.